Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that pioneered the development of RNA interference (RNAi) therapeutics. The company utilizes small interfering RNA (siRNA) to silence specific messenger RNA (mRNA) molecules, preventing the production of disease-causing proteins. Their platform focuses on genetic medicines for rare and prevalent diseases, leveraging proprietary delivery technologies like GalNAc conjugates and lipid nanoparticles.
Financials
Based on Q1 2026 filing
Revenue
View metricGross Profit
View metricNet Income
View metricOperating Cash Flow
View metricFree Cash Flow
View metricEPS (Diluted)
View metricBusiness Segments
Commercial Medicines
primaryThe primary revenue-generating division focused on the global commercialization of approved RNAi therapeutics for rare and specialty diseases. This segment manages product sales, patient access, and marketing for the company's first-in-class portfolio.
AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO, Leqvio, Qfitlia
Specialized medical centers, Hospitals, Pharmacies, Government healthcare agencies
Research and Development
moderateFocuses on advancing a pipeline of siRNA candidates through clinical trials and developing novel delivery platforms for extrahepatic tissues. This segment targets indications in the central nervous system, ocular, and cardiovascular therapeutic areas.
vutrisiran, patisiran, givosiran, lumasiran, inclisiran, fitusiran
Clinical trial participants, Research institutions, Strategic pharmaceutical partners
Business Overview
Competitive Position
Alnylam is the industry leader in RNAi therapeutics, holding the first-mover advantage with multiple approved products and a dominant intellectual property position in siRNA delivery.
Geographies
United States, European Union, Global
Customer Segments
Healthcare providers, Patients with rare genetic diseases, Global pharmaceutical companies
Upstream Dependencies
Specialized chemical suppliers, Contract manufacturing organizations, Genomic research databases
Downstream Customers
Wholesale drug distributors, Specialty pharmacies, Health insurance providers, Public health systems
Competitors & Partners
Competitors
Alnylam Pharmaceuticals FAQ
Common questions about Alnylam Pharmaceuticals
Alnylam Pharmaceuticals is a global commercial-stage biopharmaceutical company that pioneered the development of RNA interference (RNAi) therapeutics. The company utilizes small interfering RNA (siRNA) to silence specific messenger RNA (mRNA) molecules, preventing the production of disease-causing proteins. Their platform focuses on genetic medicines for rare and prevalent diseases, leveraging proprietary delivery technologies like GalNAc conjugates and lipid nanoparticles.
Alnylam Pharmaceuticals (ALNY) has a market capitalization of $40.3B and trades on NASDAQ.
Alnylam Pharmaceuticals generated $4.3B in trailing twelve-month revenue with net income of $502.3M, representing a net margin of 11.7%. Gross margin stands at 81.0%, with free cash flow of $643.3M. These figures are based on the Q1 2026 filing.
Alnylam Pharmaceuticals's key competitors include Moderna, Ionis Pharmaceuticals, Arrowhead Pharmaceuticals, and others. These companies compete in similar markets and product categories.
Alnylam Pharmaceuticals has approximately 2,100 employees.